IL324488A - Switch Receptors - Google Patents
Switch ReceptorsInfo
- Publication number
- IL324488A IL324488A IL324488A IL32448825A IL324488A IL 324488 A IL324488 A IL 324488A IL 324488 A IL324488 A IL 324488A IL 32448825 A IL32448825 A IL 32448825A IL 324488 A IL324488 A IL 324488A
- Authority
- IL
- Israel
- Prior art keywords
- cell
- domain
- seq
- chimeric receptor
- receptor polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23177793 | 2023-06-06 | ||
| PCT/EP2024/064471 WO2024251547A1 (en) | 2023-06-06 | 2024-05-27 | Switch receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324488A true IL324488A (en) | 2026-01-01 |
Family
ID=86731992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324488A IL324488A (en) | 2023-06-06 | 2024-05-27 | Switch Receptors |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4724086A1 (es) |
| JP (1) | JP2026524081A (es) |
| KR (1) | KR20260020404A (es) |
| CN (1) | CN121240874A (es) |
| AR (1) | AR132786A1 (es) |
| AU (1) | AU2024286646A1 (es) |
| CL (1) | CL2025003759A1 (es) |
| CO (1) | CO2025016585A2 (es) |
| CR (1) | CR20250523A (es) |
| IL (1) | IL324488A (es) |
| MX (1) | MX2025014670A (es) |
| PE (1) | PE20260557A1 (es) |
| TW (1) | TW202506711A (es) |
| WO (1) | WO2024251547A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3056837A1 (en) | 2017-03-27 | 2018-10-04 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| BR112022003553A2 (pt) * | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| WO2022029051A1 (en) | 2020-08-03 | 2022-02-10 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| WO2022032042A1 (en) * | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12 receptor synthetic cytokines and methods of use |
| WO2023081813A1 (en) * | 2021-11-05 | 2023-05-11 | St. Jude Children's Research Hospital, Inc. | Zip cytokine receptors |
-
2024
- 2024-05-27 EP EP24729987.8A patent/EP4724086A1/en active Pending
- 2024-05-27 JP JP2025570632A patent/JP2026524081A/ja active Pending
- 2024-05-27 TW TW113119507A patent/TW202506711A/zh unknown
- 2024-05-27 AR ARP240101333A patent/AR132786A1/es unknown
- 2024-05-27 IL IL324488A patent/IL324488A/en unknown
- 2024-05-27 PE PE2025002872A patent/PE20260557A1/es unknown
- 2024-05-27 AU AU2024286646A patent/AU2024286646A1/en active Pending
- 2024-05-27 CN CN202480037572.9A patent/CN121240874A/zh active Pending
- 2024-05-27 WO PCT/EP2024/064471 patent/WO2024251547A1/en not_active Ceased
- 2024-05-27 KR KR1020257042939A patent/KR20260020404A/ko active Pending
- 2024-05-27 CR CR20250523A patent/CR20250523A/es unknown
-
2025
- 2025-11-27 CO CONC2025/0016585A patent/CO2025016585A2/es unknown
- 2025-11-28 CL CL2025003759A patent/CL2025003759A1/es unknown
- 2025-12-05 MX MX2025014670A patent/MX2025014670A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024286646A9 (en) | 2025-12-11 |
| KR20260020404A (ko) | 2026-02-11 |
| CR20250523A (es) | 2026-01-14 |
| TW202506711A (zh) | 2025-02-16 |
| CO2025016585A2 (es) | 2025-12-09 |
| EP4724086A1 (en) | 2026-04-15 |
| CL2025003759A1 (es) | 2026-01-09 |
| AU2024286646A1 (en) | 2025-11-27 |
| JP2026524081A (ja) | 2026-07-17 |
| MX2025014670A (es) | 2026-01-07 |
| CN121240874A (zh) | 2025-12-30 |
| AR132786A1 (es) | 2025-07-30 |
| WO2024251547A1 (en) | 2024-12-12 |
| PE20260557A1 (es) | 2026-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034217A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| TWI788781B (zh) | 新型改造t細胞受體及其免疫治療 | |
| KR102235202B1 (ko) | T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car) | |
| US11793894B2 (en) | Modulation of immunity and CEACAM1 activity | |
| JP2021516996A (ja) | 生物学的に関連する直交サイトカイン/受容体対 | |
| TW202023580A (zh) | 使用靶特異性融合蛋白進行tcr再程式化之組合物及方法 | |
| TW201831505A (zh) | 針對axl或ror2之嵌合抗原受體及其使用之方法 | |
| TW201839010A (zh) | T細胞受體及其針對prame陽性癌症的免疫治療 | |
| JP2020527036A (ja) | 癌免疫療法用mr1制限t細胞受容体 | |
| CN110709416A (zh) | TGF-β诱饵受体 | |
| US20230149460A1 (en) | Methods for generating engineered memory-like nk cells and compositions thereof | |
| US20240181056A1 (en) | Chimeric antigen receptor (car)-t cells | |
| CN111542547B (zh) | 对bdca2抗原具有特异性的嵌合抗原受体 | |
| JP2021519063A (ja) | 異種ターゲティング構築物を発現するリンパ球 | |
| CN112041432A (zh) | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 | |
| US20230159645A1 (en) | Multispecific binding moieties comprising pd-1 and tgf-brii binding domains | |
| US20240207312A1 (en) | Chimeric antigen receptor (car)-t cells | |
| EP4724086A1 (en) | Switch receptors | |
| HK40129273A (en) | Switch receptors | |
| US20250302879A1 (en) | Recombinant t cell receptors | |
| US20240207313A1 (en) | Chimeric antigen receptor (car)-t cells | |
| JP2026510945A (ja) | キメラ抗原受容体の長期発現に適応した細胞内シグナル伝達および共刺激ドメイン |